Surmodics Inc (SRDX) 29.48 $SRDX SurModics Shares Up

New Post Public Reply Private Reply Replies (0) Message Board

Sep 4, 2016 at 7:24 AM

Surmodics Inc (SRDX) 29.48 $SRDX

SurModics Shares Up 40.8% Since SmarTrend's Buy Recommendation (SRDX)
Comtex SmarTrend(R) - Fri Sep 02, 12:49PM CDT
SmarTrend identified an Uptrend for SurModics (NASDAQ:SRDX) on January 28th, 2016 at $20.44. In approximately 7 months, SurModics has returned 40.84% as of today's recent price of $28.78.
SRDX: 29.48 (+1.24)

SurModics Has Returned 41.2% Since SmarTrend Recommendation (SRDX)
Comtex SmarTrend(R) - Fri Aug 26, 12:17AM CDT
SmarTrend identified an Uptrend for SurModics (NASDAQ:SRDX) on January 28th, 2016 at $20.44. In approximately 7 months, SurModics has returned 41.23% as of today's recent price of $28.86.
SRDX: 29.48 (+1.24)

Surmodics to Present at 5th Annual InvestMNt Conference on August 24
BusinessWire - Tue Aug 16, 7:05AM CDT
Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that the Company will present at the 2016 InvestMNt conference sponsored by CFA Society Minnesota.
SRDX: 29.48 (+1.24)

39.0% Return Seen to Date on SmarTrend SurModics Call (SRDX)
Comtex SmarTrend(R) - Thu Aug 11, 12:16AM CDT
SmarTrend identified an Uptrend for SurModics (NASDAQ:SRDX) on January 28th, 2016 at $20.44. In approximately 7 months, SurModics has returned 39.03% as of today's recent price of $28.41.
SRDX: 29.48 (+1.24)

Shares of SRDX Up 36.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Aug 03, 12:42PM CDT
SmarTrend identified an Uptrend for SurModics (NASDAQ:SRDX) on January 28th, 2016 at $20.44. In approximately 6 months, SurModics has returned 36.63% as of today's recent price of $27.92.
SRDX: 29.48 (+1.24)

Surmodics IVD Launches Breakthrough StabilBlock(R) Immunoassay Stabilizer
BusinessWire - Mon Aug 01, 6:05AM CDT
Surmodics, Inc. (NASDAQ: SRDX), the global leader in chemical components for in vitro diagnostic (IVD) tests and microarrays, has announced the launch and immediate availability of StabilBlock(R), its most advanced Immunoassay Stabilizer. StabilBlock Immunoassay Stabilizer is the best available reagent for reducing non-specific binding to boost immunoassay signal-to-noise ratios.
SRDX: 29.48 (+1.24)

Surmodics Reports Third Quarter Fiscal 2016 Results
BusinessWire - Thu Jul 28, 6:30AM CDT
--GAAP EPS of $0.30, Non-GAAP EPS of $0.37
SRDX: 29.48 (+1.24)

Myriad Genetics Buys Sividon Diagnostics, Gains EndoPredict
Zacks Equity Research - Zacks Investment Research - Fri Jun 03, 7:59AM CDT
With the global cancer diagnostic market currently expected to grow at a CAGR of 7.6% to $168.6 billion by 2020; we expect the Sividon acquisition to open up more opportunities for Myriad (MYGN) in this market.
BSX: 24.26 (-0.07), SRDX: 29.48 (+1.24), MYGN: 20.65 (+0.21), BAX: 46.28 (+0.10)

SurModics to Present at Jefferies Healthcare Conference
BusinessWire - Wed Jun 01, 7:05AM CDT
SurModics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced that Gary Maharaj, president and chief executive officer, and Andy LaFrence, vice president of finance and chief financial officer, will make a presentation to the investment community at the Jefferies Healthcare Conference in New York City on Tuesday, June 7, 2016, at 4 p.m. ET (3 p.m. CT).
SRDX: 29.48 (+1.24)

GNC Holdings Q1 Results Weak, Overseas Prospects Bright
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 7:01AM CDT
GNC Holdings (GNC) made a disappointing start to its first quarter of 2016 with the results squarely missing the Zacks Consensus Estimate.
BSX: 24.26 (-0.07), SRDX: 29.48 (+1.24), BAX: 46.28 (+0.10), GNC: 20.74 (-0.07)

Thermo Fisher to Buy FEI, Boost Electron Microscopy Platform
Zacks Equity Research - Zacks Investment Research - Tue May 31, 7:58AM CDT
The FEI deal is expected to be accretive to Thermo Fisher's (TMO) adjusted EPS by 30 cents in the first full year after close.
BSX: 24.26 (-0.07), SRDX: 29.48 (+1.24), TMO: 151.18 (+0.23), BAX: 46.28 (+0.10), FEIC: 106.61 (+0.05)

IDEXX Laboratories: Strong Instrument Placement Drives Q1
Zacks Equity Research - Zacks Investment Research - Mon May 30, 7:12AM CDT
IDEXX (IDXX) started off 2016 on a strong note, with its first-quarter results squarely beating the Zacks Consensus Estimate.
BSX: 24.26 (-0.07), SRDX: 29.48 (+1.24), BAX: 46.28 (+0.10), IDXX: 114.09 (+0.93)

Cepheid: GeneXpert Placements High, Currency Woes Stay
Zacks Equity Research - Zacks Investment Research - Fri May 27, 6:51AM CDT
Cepheid (CPHD) started 2016 on a promising note with its first-quarter results squarely beating the Zacks Consensus Estimate.
BSX: 24.26 (-0.07), SRDX: 29.48 (+1.24), BAX: 46.28 (+0.10), CPHD: 34.42 (+0.16)

Qiagen, Therawis Diagnostics to Develop Breast Cancer Test
Zacks Equity Research - Zacks Investment Research - Fri May 27, 6:47AM CDT
With the global cancer diagnostic market expected to grow at a CAGR of 7.6% to $168.6 billion by 2020, we expect Qiagen (QGEN) to garner higher profits on account of this collaboration.
BSX: 24.26 (-0.07), SRDX: 29.48 (+1.24), BAX: 46.28 (+0.10), QGEN: 26.63 (+0.17)

ResMed Posts Mixed Q3 Results, Brightree Buyout on Track
Zacks Equity Research - Zacks Investment Research - Thu May 26, 7:35AM CDT
ResMed (RMD) posted a lackluster third-quarter fiscal 2016. Nevertheless, ResMed's segmental as well as geographical performance was strong.
BSX: 24.26 (-0.07), SRDX: 29.48 (+1.24), BAX: 46.28 (+0.10), RMD: 67.06 (-0.06)

ResMed: Positive CAT-HF Study Results to Drive ASV Sales
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:51AM CDT
The positive CAT-HF study results encourage us to expect a rise in demand for the wide range of products offered by ResMed (RMD) in the respiratory care market.
BSX: 24.26 (-0.07), SRDX: 29.48 (+1.24), BAX: 46.28 (+0.10), RMD: 67.06 (-0.06)

Edwards Lifesciences: Q1 Strong, TAVR Prospects Bright
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:50AM CDT
Edwards Lifesciences (EW) made a strong start to 2016, with its first-quarter results beating estimates on both the fronts.
BSX: 24.26 (-0.07), SRDX: 29.48 (+1.24), BAX: 46.28 (+0.10), EW: 115.85 (-0.02)

Baxter Unveils THERANOVA Dialyser at ERA-EDTA Congress
Zacks Equity Research - Zacks Investment Research - Wed May 25, 7:42AM CDT
Baxter International Inc. (BAX) recently showcased THERANOVA, a new class of medium cut-off (MCO) dialysers.
SRDX: 29.48 (+1.24), IRMD: 17.31 (-0.30), MASI: 59.90 (+0.47), BAX: 46.28 (+0.10)

Baxter (BAX) Raised to Strong Buy on Estimate Revisions
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:22AM CDT
On May 20, Zacks Investment Research raised Baxter International Inc. (BAX) to a Zacks Rank #1 (Strong Buy).
SRDX: 29.48 (+1.24), MASI: 59.90 (+0.47), BAX: 46.28 (+0.10), EW: 115.85 (-0.02)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Championing Change: USTA Mid-Atlantic Gala's Impact

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Viking Ventures: Impacts of VK2735 on Obesity Examined

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

EZaccessMD Data Breach: Class Action Lawsuit Looms

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

D-Wave Quantum Hit with Securities Fraud Lawsuit

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Beef 'O' Brady's Expands Into Tuscaloosa Market

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

IDEAYA's IDE101: A New Front in Cancer Battle

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...